This suggestion could be supported by a perspective that differentiation promotion might be one novel anti-osteosarcoma therapeutic strategy [25] and by the increasing data finding a positive correlation between SCD-1 activity inhibition and cancer cell death [26,27,28]. The gene discussed is SCD; the disease is osteosarcoma.